Payment overview · 2025
General Payments
$398.02
8 reported records · 8 companies
Healthcare provider profile · identity verified
Mark L Stevens, MD
Allopathic & Osteopathic Physicians|Family Medicine · VICTORIA, TX · NPI 1427033786
Verified facts
What the public records show
CMS Open Payments records show Mark L Stevens, MD received $398.02 in general payments during 2025 across 8 reported records.
Shionogi Inc accounted for 31.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 10 associated products.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Shionogi Inc | Unresolved — no canonical attribution shown | $125.01 | 31.4% | 1 | 2025 |
| La Jolla Pharmaceutical Company | Unresolved — no canonical attribution shown | $124.99 | 31.4% | 1 | 2025 |
| Organogenesis Inc. | Unresolved — no canonical attribution shown | $37.81 | 9.5% | 1 | 2025 |
| Dentsply Sirona Inc | Unresolved — no canonical attribution shown | $34.66 | 8.7% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $25.26 | 6.3% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $18.54 | 4.7% | 1 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $17.50 | 4.4% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $14.25 | 3.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $398.02 | 8 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Fetroja Normalized: fetroja |
Drug | Shionogi Inc | $125.01 | 1 | 2025 |
Source payment records
|
|||||
| ZEVTERA Normalized: zevtera |
Drug | La Jolla Pharmaceutical Company | $124.99 | 1 | 2025 |
Source payment records
|
|||||
| AFFINITY Normalized: affinity |
Medical Supply | Organogenesis Inc. | $37.81 | 1 | 2025 |
Source payment records
|
|||||
| ASTRA TECH Implant System Normalized: astra tech implant system |
Device | Dentsply Sirona Inc | $34.66 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $25.26 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $25.26 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $18.54 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $18.54 | 1 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $17.50 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $14.25 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
No publishable same-company prescribing overlap was found in the loaded Part D year. This does not mean the doctor never prescribed a drug reported elsewhere by a paying company.
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 273 | 35 |
| Levothyroxine Sodium | Levothyroxine Sodium | 200 | 24 |
| Eliquis | Apixaban | 189 | 17 |
| Gabapentin | Gabapentin | 169 | 22 |
| Potassium Chloride | Potassium Chloride | 167 | 28 |
| Furosemide | Furosemide | 163 | 21 |
| Famotidine | Famotidine | 159 | 24 |
| Donepezil Hcl | Donepezil Hcl | 156 | 20 |
| Losartan Potassium | Losartan Potassium | 150 | 22 |
| Amlodipine Besylate | Amlodipine Besylate | 140 | 24 |
| Metoprolol Succinate | Metoprolol Succinate | 126 | 14 |
| Trazodone Hcl | Trazodone Hcl | 122 | 17 |
| Lisinopril | Lisinopril | 121 | 16 |
| Memantine Hcl | Memantine Hcl | 117 | 16 |
| Duloxetine Hcl | Duloxetine Hcl | 114 | suppressed |
| Metformin Hcl | Metformin Hcl | 102 | 15 |
| Escitalopram Oxalate | Escitalopram Oxalate | 96 | 13 |
| Metoprolol Tartrate | Metoprolol Tartrate | 94 | 11 |
| Myrbetriq | Mirabegron | 94 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 88 | 11 |
| Divalproex Sodium Er | Divalproex Sodium | 81 | suppressed |
| Tamsulosin Hcl | Tamsulosin Hcl | 79 | 14 |
| Divalproex Sodium | Divalproex Sodium | 72 | 13 |
| Clopidogrel | Clopidogrel Bisulfate | 67 | suppressed |
| Pantoprazole Sodium | Pantoprazole Sodium | 62 | 12 |
| Digoxin | Digoxin | 57 | suppressed |
| Ezetimibe | Ezetimibe | 57 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 55 | suppressed |
| Jardiance | Empagliflozin | 55 | suppressed |
| Levetiracetam | Levetiracetam | 54 | suppressed |
| Aripiprazole | Aripiprazole | 49 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 48 | suppressed |
| Carvedilol | Carvedilol | 47 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 46 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 46 | 22 |
| Rivastigmine | Rivastigmine Tartrate | 45 | suppressed |
| Spironolactone | Spironolactone | 43 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 42 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 40 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 40 | suppressed |
| Mirtazapine | Mirtazapine | 40 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 40 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 39 | suppressed |
| Xarelto | Rivaroxaban | 39 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 37 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 35 | suppressed |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 34 | 12 |
| Clonazepam | Clonazepam | 34 | suppressed |
| Omeprazole | Omeprazole | 34 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 33 | 13 |
| Zolpidem Tartrate | Zolpidem Tartrate | 33 | suppressed |
| Simvastatin | Simvastatin | 32 | suppressed |
| Latanoprost | Latanoprost | 31 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 30 | suppressed |
| Baclofen | Baclofen | 29 | suppressed |
| Pregabalin | Pregabalin | 29 | suppressed |
| Olanzapine | Olanzapine | 28 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 28 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 26 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 25 | suppressed |
| Rivastigmine | Rivastigmine | 25 | suppressed |
| Sucralfate | Sucralfate | 25 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 24 | 11 |
| Meclizine Hcl | Meclizine Hcl | 24 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 24 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 23 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 22 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 22 | suppressed |
| Primidone | Primidone | 22 | suppressed |
| Calcitriol | Calcitriol | 21 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 21 | 15 |
| Buspirone Hcl | Buspirone Hcl | 20 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 20 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 20 | suppressed |
| Alprazolam | Alprazolam | 19 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 19 | suppressed |
| Cephalexin | Cephalexin | 19 | suppressed |
| Finasteride | Finasteride | 19 | suppressed |
| Lamotrigine | Lamotrigine | 18 | suppressed |
| Novolog Flexpen | Insulin Aspart | 18 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 18 | suppressed |
| Trulicity | Dulaglutide | 18 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 17 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 17 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 17 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 17 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 16 | suppressed |
| Bumetanide | Bumetanide | 16 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 16 | suppressed |
| Gemtesa | Vibegron | 16 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 16 | suppressed |
| Cefdinir | Cefdinir | 15 | suppressed |
| Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 15 | suppressed |
| Mupirocin | Mupirocin | 15 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 15 | suppressed |
| Cinacalcet Hcl | Cinacalcet Hcl | 14 | suppressed |
| Clonidine | Clonidine | 14 | suppressed |
| Folic Acid | Folic Acid | 14 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 13 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 13 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Gemfibrozil | Gemfibrozil | 13 | suppressed |
| Methotrexate | Methotrexate Sodium | 13 | suppressed |
| Prednisone | Prednisone | 13 | suppressed |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 13 | suppressed |
| Ranolazine Er | Ranolazine | 13 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 12 | suppressed |
| Enulose | Lactulose | 12 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 12 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 12 | suppressed |
| Methocarbamol | Methocarbamol | 12 | suppressed |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 12 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 12 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 12 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 11 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 11 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 11 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 11 | suppressed |
| Ketoconazole | Ketoconazole | 11 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 11 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 11 | suppressed |
| Synjardy | Empagliflozin/Metformin Hcl | 11 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $398.02 · 8 records | Shionogi Inc | AFFINITY, ASTRA TECH Implant System, Cologuard Collection Kit, Fetroja, NEXLETOL, Ozempic, QULIPTA, Rybelsus, UBRELVY, ZEVTERA | — | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error